The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A new HIV prevention shot, approved by the FDA and taken just twice a year, could transform global care, but experts warn ...

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The Food and Drug Administration approved a new vaccine to prevent HIV infection, lenacapavir, a long-acting injection, which ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses KITE-363, an anti-CD19/CD20 chimeric antigen receptor T-cell therapy, being studied for patients with ...

The U.S. Food and Drug Administration has approved a groundbreaking HIV prevention shot that only needs to be taken twice a year. Medical experts are calling it one of the most significant ...

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...